BioCentury | Aug 1, 2019
Distillery Therapeutics

Osteoblast-specific HIVEP3 inhibition to treat osteoporosis

...bone tropism in large animals. Aspa Therapeutics is a subsidiary of BridgeBio Pharma Inc. TARGET/MARKER/PATHWAY: Human immunodeficiency virus type I enhancer binding protein 3 (HIVEP3)...
...email: guangping.gao@umassmed.edu CONTACT: Jae-Hyuck Shim, same affiliation as above email: jaehyuck.shim@umassmed.edu Claire Quang University of Massachusetts Medical School Human immunodeficiency virus type I enhancer binding protein 3 (HIVEP3) Osteoporosis...
BioCentury | Jun 7, 2018
Translation in Brief

New Therapeutic Targets and Biomarkers: May 2018

...treat TB and reduce drug resistance. Weill Cornell Medical College Distillery Therapeutics Musculoskeletal Bone repair Human immunodeficiency virus type I enhancer binding protein 3 (HIVEP3)...
BioCentury | May 23, 2018
Distillery Therapeutics

Musculoskeletal

...expression, respectively. Next steps include developing methods to improve delivery of SLIT3 to bone. TARGET/MARKER/PATHWAY: Human immunodeficiency virus type I enhancer binding protein 3 (HIVEP3)...
...CONTACT: Matthew Greenblatt, Cornell University, New York, N.Y. email: mag3003@med.cornell.edu Claire Quang Cornell University Dana-Farber Cancer Institute Harvard Medical School Human immunodeficiency virus type I enhancer binding protein 3 (HIVEP3) Slit...
Items per page:
1 - 3 of 3